

27. The isolated anti-PD-L1 construct of claim 25, wherein the C-terminus of the sdAb moiety specifically recognizing PD-L1 is fused to the N-terminus of at least one of the heavy chains of the full-length antibody.
28. The isolated anti-PD-L1 construct of any one of claims 25-27, wherein the full-length antibody specifically recognizes a polypeptide selected from the group consisting of TIGIT, TIM-3, and LAG-3.
29. The isolated anti-PD-L1 construct of any one of claims 25-28, wherein the PD-L1 specifically recognized by the sdAb moiety comprises the amino acid sequence of SEQ ID NO: 441-442.
30. The isolated anti-PD-L1 construct of any one of claims 25-28, wherein the sdAb moiety specifically recognizing PD-L1 and the second antibody moiety are optionally connected by a peptide linker.
31. The isolated anti-PD-L1 construct of claim 280, wherein the peptide linker comprises the amino acid sequence of SEQ ID NO: 443-445.
32. A second isolated anti-PD-L1 construct that specifically binds to PD-L1 competitively with the isolated anti-PD-L1 construct of any one of claims 1-31.
33. The second isolated anti-PD-L1 construct of claim 32, wherein the second isolated anti-PD-L1 construct comprises a CDR1 comprising the amino acid sequence of any one of SEQ ID NOs: 51-100, or a variant thereof comprising up to about 3 amino acid substitutions; a CDR2 comprising the amino acid sequence of any one of SEQ ID NOs: 151-200, or a variant thereof comprising up to about 3 amino acid substitutions; and a CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 251-300, or a variant thereof comprising up to about 3 amino acid substitutions.
34. A pharmaceutical composition comprising the isolated anti-PD-L1 construct of any one of claims 1-33, and a pharmaceutical acceptable carrier.
35. Use of the pharmaceutical composition of claim 34 in the manufacture of a medicament for the treatment of an individual having a PD-L1-related disease.
36. The use of claim 35, wherein the PD-L1 related disease is cancer.
37. The use of claim 36, wherein the cancer is a solid tumor.
38. The use of claim 36 or 37, wherein the cancer is a colon cancer.
39. The use of any one of claims 36-38, formulated to be administered with an additional cancer therapy.
40. The method of claim 39, wherein the additional cancer therapy is surgery, radiation, chemotherapy, immunotherapy, hormone therapy, or a combination thereof.
41. The method of claim 35, wherein the PD-L1 related disease is a pathogenic infection.
42. The method of any one of claims 35-41, wherein the pharmaceutical composition is formulated to be administered systemically or locally.

43. The method of claim 42, wherein the pharmaceutical composition is formulated to be administered intravenously.
44. The method of claim 42, wherein the pharmaceutical composition is formulated to be administered intratumorally.
45. The method of any one of claims 35-44, wherein the individual is a human.